COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE CROHN'S DISEASE IN GREECE

被引：0
|
作者：
Vellopoulou, K. [1 ]
Lioliou, K. [1 ]
Papantoniou, P. [2 ]
Kotsis, I [2 ]
机构：
[1] Econcare LP, Athens, Greece
[2] AbbVie Hellas, Athens, Greece
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE94
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF REMDESIVIR FOR THE TREATMENT OF COVID-19 IN GREECE
    Athanasakis, K.
    Nomikos, N.
    Tsoulas, C.
    Zisis, K.
    VALUE IN HEALTH, 2022, 25 (12) : S159 - S159
  • [42] ENDOSCOPIC AND CLINICAL OUTCOMES OF UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE BY BASELINE DISEASE SEVERITY
    Siegmund, Britta
    Patel, Kamal V.
    Torres, Esther A.
    Lakatos, Peter L.
    Seidelin, Jakob B.
    Fleisher, Mark
    Ford, Sharanya
    Remple, Valencia
    Lacerda, Ana P.
    Anyanwu, Samuel
    Garrison, Andrew
    Panes, Julian
    GASTROENTEROLOGY, 2023, 164 (06) : S1103 - S1103
  • [43] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [44] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Tsao, Nicole W.
    Shojania, Kam
    Marra, Carlo A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
  • [45] Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in Greece
    Tzanetakos, Charalampos
    Psarra, Marina
    Kotsis, Ilias
    Gourzoulidis, George
    VALUE IN HEALTH REGIONAL ISSUES, 2025, 46
  • [46] COST-EFFECTIVENESS ANALYSIS OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREECE
    Tzanetakos, C.
    Psarra, M.
    Kotsis, I
    Gourzoulidis, G.
    VALUE IN HEALTH, 2023, 26 (12) : S144 - S144
  • [47] COST-EFFECTIVENESS ANALYSIS OF ADALIMUMAB VS. CERTOLIZUMAB MAINTENANCE THERAPIES FOR MODERATE TO SEVERE CROHN'S DISEASE
    Johnson, S.
    Kaltenboeck, A.
    Horn, C.
    Mulani, P.
    Majethia, S.
    Chao, J.
    VALUE IN HEALTH, 2009, 12 (03) : A59 - A59
  • [48] COST-UTILITY AND BUDGET IMPACT ANALYSES OF INFLIXIMAB AND ITS BIOSIMILAR IN THAI PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE
    Phisalprapa, P.
    Kositamongkol, C.
    Chaiyakunapruk, N.
    VALUE IN HEALTH, 2019, 22 : S618 - S619
  • [49] COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY
    Toumi, M.
    Lamure, M.
    Grishchenko, M.
    Cochran, J.
    Rive, B.
    VALUE IN HEALTH, 2009, 12 (07) : A370 - A370
  • [50] COST-EFFECTIVENESS ANALYSIS OF BIOLOGIC AGENTS IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: A SYSTEMATIC LITERATURE REVIEW
    Sokolova, V
    Tolkacheva, D.
    VALUE IN HEALTH, 2019, 22 : S375 - S376
12345